Edition:
United Kingdom

Verastem Inc (VSTM.OQ)

VSTM.OQ on NASDAQ Stock Exchange Global Market

8.31USD
20 Jul 2018
Change (% chg)

$0.18 (+2.21%)
Prev Close
$8.13
Open
$8.08
Day's High
$8.56
Day's Low
$7.97
Volume
389,441
Avg. Vol
399,879
52-wk High
$9.07
52-wk Low
$2.78

Latest Key Developments (Source: Significant Developments)

Verastem Oncology Announces $43.0 Million Offering Of Common Stock
Thursday, 14 Jun 2018 

June 14 (Reuters) - Verastem Inc ::VERASTEM ONCOLOGY ANNOUNCES $43.0 MILLION OFFERING OF COMMON STOCK.VERASTEM INC - OFFERING OF COMMON STOCK STOCK AT A PRICE OF $6.00 PER SHARE.  Full Article

Verastem's Julie Feder Resigned As Chief Financial Officer
Friday, 1 Jun 2018 

June 1 (Reuters) - Verastem Inc ::VERASTEM SAYS ON MAY 30, 2018, JULIE FEDER RESIGNED AS CHIEF FINANCIAL OFFICER OF VERASTEM - SEC FILING.VERASTEM INC - EFFECTIVE MAY 31, DANIEL PATERSON CO'S COO WILL SERVE AS PRINCIPAL FINANCIAL OFFICER ON AN INTERIM BASIS.  Full Article

Verastem Oncology Announces Public Offering Of Common Stock
Tuesday, 15 May 2018 

May 15 (Reuters) - Verastem Inc ::VERASTEM ONCOLOGY ANNOUNCES PUBLIC OFFERING OF COMMON STOCK.VERASTEM INC - COMMENCED A REGISTERED UNDERWRITTEN PUBLIC OFFERING OF $35 MILLION OF ITS SHARES OF COMMON STOCK.VERASTEM INC - HAS COMMENCED A REGISTERED UNDERWRITTEN PUBLIC OFFERING OF $35 MILLION OF ITS SHARES OF COMMON STOCK.  Full Article

Verastem Announces Increased Hercules Debt Facility
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Verastem Inc ::VERASTEM ANNOUNCES INCREASED HERCULES DEBT FACILITY.VERASTEM INC - ANNOUNCED ENTRY INTO AN AMENDMENT TO ITS LOAN AND SECURITY AGREEMENT WITH HERCULES CAPITAL INC.VERASTEM INC - ‍INCREASING ITS EXISTING BORROWING LIMIT UNDER LOAN FACILITY FROM $25 MILLION TO UP TO $50 MILLION IN FINANCING​.VERASTEM INC - ‍VERASTEM HAS RECEIVED FIRST $15 MILLION OF FINANCING UNDER ORIGINAL LOAN AND SECURITY AGREEMENT​.VERASTEM - ‍INCREASED LOAN FACILITY PROCEEDS TO BE USED FOR DEVELOPMENT PROGRAMS, INCLUDING REGULATORY & COMMERCIALIZATION ACTIVITIES FOR DUVELISIB​.  Full Article

Verastem Announces Pricing Of Public Offering Of Common Stock
Friday, 15 Dec 2017 

Verastem Inc ::VERASTEM ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.VERASTEM INC - ANNOUNCED PRICING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF APPROXIMATELY $25 MILLION OF SHARES OF ITS COMMON STOCK.  Full Article

Verastem Announces Public Offering Of Common Stock
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Verastem Inc ::VERASTEM ANNOUNCES PUBLIC OFFERING OF COMMON STOCK.VERASTEM INC - INTENDS TO OFFER AND SELL $25 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.  Full Article

‍Verastem Announces Clinical Data From Pivotal Phase 3 Duo Study​
Sunday, 10 Dec 2017 

Dec 10 (Reuters) - Verastem Inc ::‍VERASTEM ANNOUNCES CLINICAL DATA FROM PIVOTAL PHASE 3 DUO™ STUDY​.‍DUO STUDY ACHIEVES PRIMARY ENDPOINT, DEMONSTRATING STATISTICALLY SIGNIFICANT IMPROVEMENT IN PFS FOR DUVELISIB VERSUS OFATUMUMAB​.‍PLANS TO SUBMIT A NDA TO U.S. FDA REQUESTING FULL APPROVAL OF DUVELISIB​.‍PLANS TO SUBMIT ACCELERATED APPROVAL OF DUVELISIB FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY FL ​.‍EXPECTS TO SUBMIT DUVELISIB NDA DURING Q1 OF 2018​.  Full Article

Verastem reports Q3 loss per share of $0.61
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Verastem Inc :Verastem reports third quarter 2017 financial results.Q3 loss per share $0.61.Q3 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S.Verastem - based on current plans,​ ‍expect to have sufficient cash, cash equivalents & investments to fund research and development programs & operations into H2 2018.  Full Article

Verastem says ‍plans to submit NDA for duvelisib during Q1 of 2018​
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Verastem Inc -:Verastem announces regulatory strategy for duvelisib, new drug application following guidance from FDA.Verastem Inc - ‍plans to submit NDA for duvelisib during Q1 of 2018​.  Full Article

Verastem reports Q2 loss per share $0.23
Monday, 8 Aug 2016 

Verastem Inc : Verastem reports second quarter 2016 financial results . Q2 loss per share $0.23 . Q2 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S .Expect to have sufficient cash, cash equivalents and short-term investments to fund research and development programs and operations into 2018.  Full Article